Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisabeth Schorb

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
The Lancet. Haematology|February 1, 2024
High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trialElisabeth Schorb, Lisa Kristina Isbell, Andrea Kerkhoff, et al.
NPJ Precision Oncology|August 14, 2024
Comprehensive genetic profiling and molecularly guided treatment for patients with primary CNS tumorsJulia C Kuehn, Patrick Metzger, Nicolas Neidert, et al.
Hemasphere|June 24, 2026
Spatial and multi-omic profiling reveals pericyte-derived CCL19 as a key prognostic factor in CNS lymphomaJulia C Kuehn, Lauritz Miarka, Roman Sankowski, et al.
The Lancet. Haematology|May 3, 2016
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trialAndrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2026
High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter AnalysisMatthew R Wilson, Katharine L Lewis, Amy A Kirkwood, et al.
The Lancet. Haematology|October 22, 2017
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trialAndrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, et al.
Leukemia|May 13, 2022
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trialAndrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, et al.
Blood|January 7, 2022
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patientsMatthew R Wilson, Toby A Eyre, Amy A Kirkwood, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
The Lancet. Haematology|February 1, 2024
High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trialElisabeth Schorb, Lisa Kristina Isbell, Andrea Kerkhoff, et al.
NPJ Precision Oncology|August 14, 2024
Comprehensive genetic profiling and molecularly guided treatment for patients with primary CNS tumorsJulia C Kuehn, Patrick Metzger, Nicolas Neidert, et al.
Hemasphere|June 24, 2026
Spatial and multi-omic profiling reveals pericyte-derived CCL19 as a key prognostic factor in CNS lymphomaJulia C Kuehn, Lauritz Miarka, Roman Sankowski, et al.
The Lancet. Haematology|May 3, 2016
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trialAndrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2026
High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter AnalysisMatthew R Wilson, Katharine L Lewis, Amy A Kirkwood, et al.
The Lancet. Haematology|October 22, 2017
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trialAndrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, et al.
Leukemia|May 13, 2022
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trialAndrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, et al.
Blood|January 7, 2022
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patientsMatthew R Wilson, Toby A Eyre, Amy A Kirkwood, et al.
Pageof 5